Personal information

Other IDs

Scopus Author ID: 55773761400

Activities

Collapse all

Employment (1)

City of Hope National Medical Center: Duarte, CA, US

2009-01-01 to present | Associate Professor (Hematology & Hematopoietic Cell Transplantation)
Employment
Source: Self-asserted source
Tanya Siddiqi

Works (50 of 80)

Items per page:
Page 1 of 2

CARs vs bispecifics: the race is on!

Blood
2024-08-08 | Journal article
DOI: 10.1182/blood.2024025130
Contributors: Tanya Siddiqi
Source: check_circle
Crossref

Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials

Blood Advances
2024-07-09 | Journal article
DOI: 10.1182/bloodadvances.2023011307
Contributors: Matthew S. Davids; Jeff P. Sharman; Paolo Ghia; Jennifer A. Woyach; Toby A. Eyre; Wojciech Jurczak; Tanya Siddiqi; Paulo Miranda; Mina Shahkarami; Anna Butturini et al.
Source: check_circle
Crossref

Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them

Cancer Drug Resistance
2024-05-14 | Journal article
DOI: 10.20517/cdr.2023.100
Contributors: Azra Borogovac; Tanya Siddiqi
Source: check_circle
Crossref

Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study

Journal of Clinical Oncology
2024-04-01 | Journal article
DOI: 10.1200/JCO.23.02214
Contributors: Michael Wang; Tanya Siddiqi; Leo I. Gordon; Manali Kamdar; Matthew Lunning; Alexandre V. Hirayama; Jeremy S. Abramson; Jon Arnason; Nilanjan Ghosh; Amitkumar Mehta et al.
Source: check_circle
Crossref

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

Clinical Cancer Research
2024-02-01 | Journal article
DOI: 10.1158/1078-0432.CCR-22-3934
Contributors: Nitin Jain; Lisa J. Croner; John N. Allan; Tanya Siddiqi; Alessandra Tedeschi; Xavier C. Badoux; Karl Eckert; Leo W.K. Cheung; Anwesha Mukherjee; James P. Dean et al.
Source: check_circle
Crossref

Data from Absence of <i>BTK</i>, <i>BCL2</i>, and <i>PLCG2</i> Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

2024-02-01 | Preprint
DOI: 10.1158/1078-0432.c.7054089
Contributors: Nitin Jain; Lisa J. Croner; John N. Allan; Tanya Siddiqi; Alessandra Tedeschi; Xavier C. Badoux; Karl Eckert; Leo W.K. Cheung; Anwesha Mukherjee; James P. Dean et al.
Source: check_circle
Crossref

Data from Absence of <i>BTK</i>, <i>BCL2</i>, and <i>PLCG2</i> Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

2024-02-01 | Preprint
DOI: 10.1158/1078-0432.c.7054089.v1
Contributors: Nitin Jain; Lisa J. Croner; John N. Allan; Tanya Siddiqi; Alessandra Tedeschi; Xavier C. Badoux; Karl Eckert; Leo W.K. Cheung; Anwesha Mukherjee; James P. Dean et al.
Source: check_circle
Crossref

Supplementary Data 1 from Absence of <i>BTK</i>, <i>BCL2</i>, and <i>PLCG2</i> Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

2024-02-01 | Preprint
DOI: 10.1158/1078-0432.25124601
Contributors: Nitin Jain; Lisa J. Croner; John N. Allan; Tanya Siddiqi; Alessandra Tedeschi; Xavier C. Badoux; Karl Eckert; Leo W.K. Cheung; Anwesha Mukherjee; James P. Dean et al.
Source: check_circle
Crossref

Supplementary Data 1 from Absence of <i>BTK</i>, <i>BCL2</i>, and <i>PLCG2</i> Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax

2024-02-01 | Preprint
DOI: 10.1158/1078-0432.25124601.v1
Contributors: Nitin Jain; Lisa J. Croner; John N. Allan; Tanya Siddiqi; Alessandra Tedeschi; Xavier C. Badoux; Karl Eckert; Leo W.K. Cheung; Anwesha Mukherjee; James P. Dean et al.
Source: check_circle
Crossref

Data from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.c.6684414.v2
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Data from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.c.6684414
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

Clinical Cancer Research
2023-07-14 | Journal article
DOI: 10.1158/1078-0432.CCR-22-2779
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.23683831.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.23683831
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.23683828.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.23683828
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.23683825
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.23683825.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S3 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.23683822.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S3 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-07-14 | Preprint
DOI: 10.1158/1078-0432.23683822
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Data from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.c.6684414.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.23307762
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Figure S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.23307762.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.23307759
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S1 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.23307759.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.23307756
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S2 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.23307756.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S3 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.23307753.v1
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Supplementary Table S3 from Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

2023-06-07 | Preprint
DOI: 10.1158/1078-0432.23307753
Contributors: John N. Allan; Ian W. Flinn; Tanya Siddiqi; Paolo Ghia; Constantine S. Tam; Thomas J. Kipps; Paul M. Barr; Anna Elinder Camburn; Alessandra Tedeschi; Xavier C. Badoux et al.
Source: check_circle
Crossref

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

Blood
2022-12-22 | Journal article
DOI: 10.1182/blood.2022016624
Contributors: Swetha Kambhampati; Monica Saumoy; Yecheskel Schneider; Stacy Pak; Lihua Elizabeth Budde; Matthew G. Mei; Tanya Siddiqi; Leslie L. Popplewell; Yi-Ping Wen; Jasmine Zain et al.
Source: check_circle
Crossref

Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

Blood
2022-11-10 | Journal article
DOI: 10.1182/blood.2022016747
Contributors: Swetha Kambhampati; Monica Saumoy; Yecheskel Schneider; Steve Serrao; Pejman Solaimani; Lihua Elizabeth Budde; Matthew G. Mei; Leslie L. Popplewell; Tanya Siddiqi; Jasmine Zain et al.
Source: check_circle
Crossref

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Blood
2022-06-02 | Journal article
DOI: 10.1182/blood.2021014488
Contributors: Constantine S. Tam; John N. Allan; Tanya Siddiqi; Thomas J. Kipps; Ryan Jacobs; Stephen Opat; Paul M. Barr; Alessandra Tedeschi; Livio Trentin; Rajat Bannerji et al.
Source: check_circle
Crossref

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Blood
2022-03-24 | Journal article
DOI: 10.1182/blood.2021011895
Contributors: Tanya Siddiqi; Jacob D. Soumerai; Kathleen A. Dorritie; Deborah M. Stephens; Peter A. Riedell; Jon Arnason; Thomas J. Kipps; Heidi H. Gillenwater; Lucy Gong; Lin Yang et al.
Source: check_circle
Crossref

Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies

Current Hematologic Malignancy Reports
2022-02 | Journal article
DOI: 10.1007/s11899-021-00652-2
Contributors: Michael Rainone; Tanya Siddiqi
Source: check_circle
Crossref

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Journal of Clinical Oncology
2022-01-01 | Journal article
DOI: 10.1200/JCO.21.01194
Contributors: Jorge J. Castillo; John N. Allan; Tanya Siddiqi; Ranjana H. Advani; Kirsten Meid; Carly Leventoff; Timothy P. White; Catherine A. Flynn; Shayna Sarosiek; Andrew R. Branagan et al.
Source: check_circle
Crossref

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Journal of Clinical Oncology
2021-12-01 | Journal article
DOI: 10.1200/JCO.21.00807
Contributors: William G. Wierda; John N. Allan; Tanya Siddiqi; Thomas J. Kipps; Stephen Opat; Alessandra Tedeschi; Xavier C. Badoux; Bryone J. Kuss; Sharon Jackson; Carol Moreno et al.
Source: check_circle
Crossref

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

Blood Advances
2021-10-26 | Journal article
DOI: 10.1182/bloodadvances.2020004106
Contributors: Tanya Siddiqi; Xiuli Wang; M. Suzette Blanchard; Jamie R. Wagner; Leslie L. Popplewell; L. Elizabeth Budde; Tracey L. Stiller; Mary C. Clark; Laura Lim; Vibhuti Vyas et al.
Source: check_circle
Crossref

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Blood Advances
2021-10-26 | Journal article
DOI: 10.1182/bloodadvances.2020003848
Contributors: Sattva S. Neelapu; Frederick L. Locke; Nancy L. Bartlett; Lazaros J. Lekakis; Patrick M. Reagan; David B. Miklos; Caron A. Jacobson; Ira Braunschweig; Olalekan O. Oluwole; Tanya Siddiqi et al.
Source: check_circle
Crossref

Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer

Molecular Cell
2021-05 | Journal article
DOI: 10.1016/j.molcel.2021.03.043
Contributors: Teresa Sadras; Mickaël Martin; Kohei Kume; Mark E. Robinson; Supraja Saravanakumar; Gal Lenz; Zhengshan Chen; Joo Y. Song; Tanya Siddiqi; Laura Oksa et al.
Source: check_circle
Crossref

A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors

Investigational New Drugs
2019 | Journal article
DOI: 10.1007/s10637-019-00768-6
EID:

2-s2.0-85064713804
Contributors: Sharman, J.P.; Wheler, J.J.; Einhorn, L.; Dowlati, A.; Shapiro, G.I.; Hilton, J.; Burke, J.M.; Siddiqi, T.; Whiting, N.; Jalal, S.I.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

JNCCN Journal of the National Comprehensive Cancer Network
2019 | Journal article
DOI: 10.6004/jnccn.2019.0002
EID:

2-s2.0-85060137075
Contributors: Wierda, W.G.; Byrd, J.C.; Abramson, J.S.; Bilgrami, S.F.; Bociek, G.; Brander, D.; Brown, J.; Chanan-Khan, A.A.; Chavez, J.C.; Coutre, S.E. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Blood
2019 | Journal article
DOI: 10.1182/blood-2019-121424
EID:

2-s2.0-85074959042
Contributors: Tam, C.S.; Siddiqi, T.; Allan, J.N.; Kipps, T.J.; Flinn, I.W.; Kuss, B.J.; Opat, S.; Barr, P.M.; Tedeschi, A.; Jacobs, R. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

The Lancet Oncology
2019 | Journal article
DOI: 10.1016/S1470-2045(18)30864-7
EID:

2-s2.0-85059501669
Contributors: Locke, F.L.; Ghobadi, A.; Jacobson, C.A.; Miklos, D.B.; Lekakis, L.J.; Oluwole, O.O.; Lin, Y.; Braunschweig, I.; Hill, B.T.; Timmerman, J.M. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies

Leukemia and Lymphoma
2019 | Journal article
DOI: 10.1080/10428194.2019.1672052
EID:

2-s2.0-85074359850
Contributors: Siddiqi, T.; Frankel, P.; Beumer, J.H.; Kiesel, B.F.; Christner, S.; Ruel, C.; Song, J.Y.; Chen, R.; Kelly, K.R.; Ailawadhi, S. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier
grade
Preferred source (of 2)‎

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

The Lancet Haematology
2019 | Journal article
DOI: 10.1016/S2352-3026(18)30216-3
EID:

2-s2.0-85060534888
Contributors: Nastoupil, L.J.; Lunning, M.A.; Vose, J.M.; Schreeder, M.T.; Siddiqi, T.; Flowers, C.R.; Cohen, J.B.; Burger, J.A.; Wierda, W.G.; O'Brien, S. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Blood
2019 | Journal article
DOI: 10.1182/blood.2019002118
EID:

2-s2.0-85075562689
Contributors: Lunning, M.; Vose, J.; Nastoupil, L.; Fowler, N.; Burger, J.A.; Wierda, W.G.; Schreeder, M.T.; Siddiqi, T.; Flowers, C.R.; Cohen, J.B. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer

Journal of the American Geriatrics Society
2019 | Journal article
DOI: 10.1111/jgs.15841
EID:

2-s2.0-85063336614
Contributors: Hsu, T.; Nathwani, N.; Loscalzo, M.; Chung, V.; Chao, J.; Karanes, C.; Koczywas, M.; Forman, S.; Lim, D.; Siddiqi, T. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

Annals of Oncology
2018 | Journal article
DOI: 10.1093/annonc/mdx791
EID:

2-s2.0-85046107364
Contributors: Herrera, A.F.; Palmer, J.; Martin, P.; Armenian, S.; Tsai, N.-C.; Kennedy, N.; Sahebi, F.; Cao, T.; Budde, L.E.; Mei, M. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

Leukemia
2018 | Journal article
DOI: 10.1038/s41375-018-0210-1
EID:

2-s2.0-85050272095
Contributors: Kreitman, R.J.; Dearden, C.; Zinzani, P.L.; Delgado, J.; Karlin, L.; Robak, T.; Gladstone, D.E.; le Coutre, P.; Dietrich, S.; Gotic, M. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier

Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

Journal of Hematology and Oncology
2018 | Journal article
DOI: 10.1186/s13045-018-0631-3
EID:

2-s2.0-85049169036
Contributors: Chen, R.W.; Palmer, J.M.; Tomassetti, S.; Popplewell, L.L.; Alluin, J.; Chomchan, P.; Nademanee, A.P.; Siddiqi, T.; Tsai, N.-C.; Chen, L. et al.
Source: Self-asserted source
Tanya Siddiqi via Scopus - Elsevier
Items per page:
Page 1 of 2

Peer review (1 review for 1 publication/grant)

Review activity for The lancet. (1)
How many people are using ORCID?